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Abstract
Background: Kaposi sarcoma (KS) is the most common AIDS-defining tumour in HIV-infected individuals in Africa.
Kaposi sarcoma herpes virus (KSHV) infection precedes development of KS. KSHV co-infection may be associated with
worse outcomes in HIV disease and elevated KSHV viral load may be an early marker for advanced HIV disease among
untreated patients. We examined the prevalence of KSHV among adults initiating antiretroviral therapy (ART) and
compared immunological, demographic and clinical factors between patients seropositive and seronegative for KSHV.
Results: We analyzed cross-sectional data collected from 404 HIV-infected treatment-naïve adults initiating ART at the
Themba Lethu Clinic, Johannesburg, South Africa between November 2008 and March 2009. Subjects were screened at
ART initiation for antibodies to KSHV lytic K8.1 and latent Orf73 antigens. Seropositivity to KSHV was defined as positive
to either lytic KSHV K8.1 or latent KSHV Orf73 antibodies. KSHV viremia was determined by quantitative PCR and CD3, 4
and 8 lymphocyte counts were determined with flow cytometry. Of the 404 participants, 193 (48%) tested positive for
KSHV at ART initiation; with 76 (39%) reactive to lytic K8.1, 35 (18%) to latent Orf73 and 82 (42%) to both. One individual
presented with clinical KS at ART initiation. The KSHV infected group was similar to those without KSHV in terms of age,
race, gender, ethnicity, smoking and alcohol use. KSHV infected individuals presented with slightly higher median CD3
(817 vs. 726 cells/mm3) and CD4 (90 vs. 80 cells/mm3) counts than KSHV negative subjects. We found no associations
between KSHV seropositivity and body mass index, tuberculosis status, WHO stage, HIV RNA levels, full blood count or
liver function tests at initiation. Those with detectable KSHV viremia (n = 19), however, appeared to present with signs
of more advanced HIV disease including anemia and WHO stage 3 or 4 defining conditions compared to those in
whom the virus was undetectable.
Conclusions: We demonstrate a high prevalence of KSHV among HIV-infected adults initiating ART in a large
urban public-sector HIV clinic. KSHV viremia but not KSHV seropositivity may be associated with markers of
advanced HIV disease.
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Background
Since there has been greater access to antiretroviral
therapy (ART) [1-3], increased longevity among those
infected with HIV has made morbidity and mortality
from cancers associated with HIV increasingly more
common [4]. Viral associated cancers including cervical
cancer, non-Hodgkin’s lymphoma and Kaposi sarcoma
(KS) are prominent among HIV-infected individuals
[4,5]. Kaposi sarcoma is the most common tumour in
HIV-infected individuals in Africa and is preceded by
infection with Kaposi sarcoma herpes virus (KSHV) [6].
Kaposi sarcoma was relatively common in South Africa
(up to 5 per 1000 population at risk) prior to the AIDS
epidemic [7] but the incidence increased dramatically as
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the epidemic escalated [4,5,8]. The incidence of KS has
decreased in the US and Europe with the introduction
of HAART [9-11] but the impact of HAART in Africa
where the underlying prevalence of KSHV is higher is
yet to be determined.
While clinical Kaposi sarcoma is known to be a marker
of advanced HIV disease and is one of the WHO stage 4
and AIDS-defining illnesses [12], it is unclear if co-infection
with oncogenic viruses such as KSHV places untreated
HIV-infected patients at similar risk even without clinically
apparent illness. Several clinical and laboratory markers
have been associated with advanced disease stage among
untreated HIV-infected individuals [13-21], including the
T-lymphocyte subpopulations, CD4+ and CD8+
[14,18,22-26] which play an important role in the response
to viral infections. While KSHV-specific CD8+ T cell epi-
tope responses have been shown to increase after initiation
of HAART [27,28], it has yet to be determined if T-lym-
phocyte subpopulations are also a marker of advanced dis-
ease stage in ART naive patients infected with KSHV (as
seen among the HIV-infected population) and if this has
implications for treatment initiation guidelines.
We enrolled subjects in a cohort study to determine
the impact of KSHV on response to HAART as well as
the effects of HAART on KSHV control. This cross-sec-
tional analysis forms part of this larger study and aimed
to measure the prevalence of KSHV infection among
these HIV-infected adults initiating ART in a large treat-
ment programme in Johannesburg, South Africa and to
compare T-lymphocyte subpopulations and other demo-
graphic, clinical and laboratory factors between patients
seropositive and seronegative for KSHV at enrolment.
Methods
Study design
This cross-sectional study utilized data from patients
enrolled in care at the Themba Lethu Clinic in Johannes-
burg, South Africa. Currently, Themba Lethu has over
23,000 HIV infected adults enrolled in its comprehensive
HIV care, management and treatment program. Since
inception, over 16,000 of these patients have been initiated
on ART at this clinic. Care at the clinic is provided accord-
ing to the guidelines from the South African National
Department of Health [29]. Patient data at Themba Lethu
is captured and stored in an electronic patient record,
TherapyEdge-HIV™. At enrolment into care, data on
demographics, physical examination and clinical diagnoses
are recorded. At initiation of ART, laboratory test results,
including CD4 lymphocyte counts, full blood counts and
liver function tests, are also recorded.
Eligibility Criteria
Between November 2008 and March 2009, all HIV-posi-
tive treatment naïve patients > 18 years of age who met
the National guidelines criteria for initiation of ART
(CD4 count < 200 cells/mm3 or WHO stage 4 defining
illness) and who were attending group counselling ses-
sions at Themba Lethu were invited to participate in the
study. Patients who did not meet these criteria or had a
history of prior ART use were excluded from the study.
Study variables
Venous blood samples were drawn from all study parti-
cipants prior to initiation of ART to determine KSHV
serostatus. Seropositivity to KSHV was defined as a
positive reaction to either lytic KSHV K8.1 or latent
KSHV Orf73 antibodies detected using enzyme-linked
immunosorbent assays (ELISA). Detection of antibodies
to a single antigen has been shown to potentially under-
estimate the prevalence of KSHV, therefore, the ELISA
to detect antibodies to latency associated nuclear anti-
gen was performed in addition to the lytic K8.1 ELISA
to provide a more accurate assessment of KSHV anti-
body status [30]. KSHV viremia was determined using
150 ng of DNA extracted from buffy coat using the
QIAamp DNA Blood Midi kit, according to the manu-
facturer’s instructions. Quantitative TaqMan PCR as per
previously published methodology [31] was performed
on the ABI Prism 7900 sequence detection system
(Applied Biosystems, Forster City, CA). Subject and con-
trol samples were run in triplicate. The KSHV viral load
assay has a linear dynamic range of 8 logs and is cali-
brated to detect a single copy of viral DNA in 150 ng
genomic DNA. CD3, CD4 and CD8 lymphocyte counts
(components of the total lymphocyte count) were per-
formed using flow cytometry and standard methodology.
Additional data was extracted from the electronic
patient record. Demographic variables of interest
included gender, age at study enrolment, race, as well as
ethnicity (using mother and father tongue as a proxy).
Clinical data on initiating ART regimen, WHO clinical
stage, body mass index (BMI), tuberculosis status and
HIV RNA level at enrolment were also extracted as well
as laboratory results for full blood counts and liver func-
tion tests.
Statistical analysis
The prevalence of KSHV among the study group was
estimated and is presented with corresponding 95% con-
fidence bounds. Demographic, clinical and laboratory
characteristics of the participants at study enrolment
were stratified by KSHV status and summarized as sim-
ple proportions or medians with interquartile ranges
(IQR). Logarithmic transformations of optical densities
for lytic K8.1 and latent Orf73 were performed and are
presented as geometric means. Crude prevalence ratios
for participant presenting features were estimated using
log-binomial regression models stratified by KSHV
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serostatus. This analysis was also further stratified by
reaction to lytic K8.1 or latent Orf73 antigen. Models
were adjusted for age, sex and presenting CD4 count
where appropriate.
Approval to conduct this study and use of data from the
Themba Lethu site was granted by the Human Research
Ethics Committee of the University of the Witwatersrand.
Results
All eligible subjects initiating ART at Themba Lethu
Clinic between November 2008 and March 2009 were
invited to participate and we enrolled 404 of these.
Response rates were high: it is estimated that fewer than
5% of those invited to participate refused. However, in
order to determine if the sample was representative of
the untreated population accessing HIV care at that
time, we compared this sample to the general popula-
tion presenting for treatment initiation at Themba
Lethu during the recruitment period that were either
not invited or refused to participate in the study. The
presenting features of the study group were very similar
to the Themba Lethu Clinic general population at ART
initiation (Table 1) in terms of age, CD4 cell count, HIV
viral load, proportion with WHO stage 3 or 4 defining
illness, hemoglobin level and BMI. The Themba Lethu
Clinic general population had a slightly lower propor-
tion of females (61% vs. 65%) and slightly lower propor-
tion presenting with tuberculosis (11% vs. 14%)
compared to the study group.
The median age of the study group was 38 years (IQR
32-45 years) and 262 (65%) were women. The median
CD4 count at ART initiation was 87 cells/μL (IQR 40-149
cells/μL) and nearly 40% presented with a WHO stage III/
IV defining condition. The majority of participants were
started on standard public-sector first-line ART regimens:
86% on stavudine, lamivudine and efavirenz and 7% on
stavudine, lamivudine and nevirapine. The remaining 7%
who presented with a contra-indication to one of the stan-
dard first-line regimens were initiated on zidovudine, lopi-
navir/ritonavir or tenofovir-based regimens.
Prevalence of KSHV
Among the study participants, 193/404 tested positive to
lytic KSHV K8.1 and/or latent KSHV Orf73 antibodies at
ART initiation; the prevalence of KSHV in this urban
population was estimated at 48% (95%CI: 43-53%). Of
those positive for KSHV, 76 (39%; 95% CI 33-46%) were
reactive to lytic K8.1 alone, 35 (18%; 95% CI13-24%) to
latent Orf73 and 82 (42%; 95%CI 36-50%) to both. Only
one individual presented with clinical KS at ART initiation.
This individual was positive to both lytic and latent KSHV
antigen but did not have a detectable KSHV viral load.
KSHV viral load
Of the 193 individuals serologically positive to KSHV,
167 (87%) had samples available for KSHV viral load
testing. KSHV DNA was detected in 19 (11%) of the
buffy coat samples of those serologically positive to
Table 1 Presenting features of 404 ART naïve adults in care at Themba Lethu in Johannesburg, South Africa stratified
by KSHV&status
Characteristics# * General Clinic Population (n = 679) KSHV+&(n = 193) KSHV-&(n = 211)
Female 416 (61%) 127 (66%) 135 (64%)
Age (yrs.) Median (IQR) 37 (31-43) 37 (32-47) 38 (32-45)
WHO Stage I/II 408 (64%) 116 (64%) 114 (61%)
(n, %) III/IV 231 (36%) 64 (36%) 74 (39%)
BMI < 18.5 118 (23%) 38 (21%) 57 (29%)
(n, %) 18.5-24.9 286 (56%) 98 (56%) 94 (48%)
25-30 72 (14%) 23 (13%) 31 (16%)
> 30 37 (7%) 15 (8%) 14 (7%)
Hemoglobin (n, %) ≤ 8.0 g/dL 41 (7%) 14 (7%) 13 (6%)
CD4 count (cells/mm3) Median (IQR) 100 (39-173) 101 (46-168) 89 (34-164)
CD4 cell count category 0-50 167 (31%) 47 (28%) 63 (34%)
(n, %) 51-100 106 (19%) 39 (23%) 39 (21%)
101-200 182 (33%) 65 (38%) 56 (30%)
200-350 89 (16%) 20 (12%) 30 (16%)
Tuberculosis (n, %) Yes 75 (11%) 26 (14%) 30 (15%)
HIV RNA Median (IQR) 20000 (8300-39000) 15500 (6400-33500) 19500 (7300-39000)
# Characteristics at eligibility for initiation of antiretroviral therapy
* Themba Lethu clinic general population refers to treatment naïve adults eligible for initiation of antiretroviral therapy during the study period who were not
recruited into the study
&KSHV = Kaposi sarcoma herpes virus
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KSHV with a median of 10.6 (IQR 6.7-37.5) copies/uL
and values ranging from 1.91 - 109.8 copies/uL. A
higher proportion of those positive to both lytic and
latent KSHV antibodies had detectable KSHV viral loads
(20%) compared to those positive to only lytic (3%) or
only latent (8%). The estimates suggested that those
with a detectable KSHV viral load were more likely to
be male (PR = 1.43; 95%CI 0.61-3.35), have a WHO
stage III/IV illnesses (PR = 1.51; 95%CI 0.65-3.50) and
hemoglobin ≤ 8 g/dL (PR = 1.42; 95%CI 0.37-5.43) com-
pared to those without a detectable KSHV viral load,
although these results lacked precision (as indicated by
the wide confidence intervals).
Associations with overall KSHV seropositivity
The KSHV infected group was similar to those without
KSHV group in terms of age, race, gender and ethnicity
(mother and father tongue). KSHV positive individuals
presented with slightly higher median CD3 (817 vs. 726
cells/mm3) and CD4 (90 vs. 80 cells/mm3) than KSHV
negative subjects (Figure 1). In log-binomial regression
models, adjusted prevalence ratios of KSHV seropositivity
was increased for those with CD3 and CD8 counts ≥ 500
cells compared to those < 500 cells and also CD4 counts
between 51 and 200 cells compared to CD4 counts ≤ 50,
(Table 2) although some of these estimates lacked preci-
sion (i.e. our confidence intervals are wide). Those with a
BMI > 18.5 kg/m2 were also more likely to be infected
with KSHV while those with Zulu as mother tongue were
somewhat less likely to be KSHV positive. We found no
association between KSHV seropositivity and several other
factors including gender, age, WHO stage and tuberculosis
status. Estimates were adjusted for gender, age and base-
line CD4 count, where appropriate.
Figure 1 Box Plots of CD3+ (top), CD4+ (middle) and CD8+ (bottom) lymphocyte counts by KSHV serostatus.
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Associations with lytic or latent antibody presence
The geometric mean of the optical density was 0.83
(95%CI 0.80-0.87) for lytic K8.1 and 0.34 (95%CI 0.32-
0.37) for latent Orf73. Presence of antibodies to latent
Orf73 was associated with higher median CD3 (863 vs.
720 cells/mm3; p = 0.019) and CD8 (706 vs. 569 cells/
mm3; p = 0.026) cell counts. Higher BMI (≥ 18.5 kg/
m2) was associated with reactivity to both lytic K8.1
[PR = 1.33 (0.94-1.90)] and latent Orf73 [PR = 1.46
(0.94-2.26)] in models adjusted for age, gender and
CD4 cell count (Table 2), while higher CD3, CD4,
CD8 counts as well as a low hemoglobin level were
associated more strongly with reactivity to latent Orf73
than lytic K8.1.
Discussion
The prevalence of KSHV is reported to be high in Africa
[32-34]. Those co-infected with KSHV and HIV are at
high risk for Kaposi sarcoma, a condition associated
with poor outcome in HIV-infected patients. This cross-
sectional analysis estimated the prevalence of KSHV
among adults initiating ART at a large urban clinic in
Johannesburg and investigated factors associated with
KSHV seropositivity and reactivity to either lytic or
latent KSHV antigen. We demonstrated a high preva-
lence of KSHV in this population and found that few
factors associated with advanced HIV disease stage and
progression were also associated with KSHV seropositiv-
ity. In fact, reactivity to latent KSHV antigen was
Table 2 Associations with lytic/latent KSHV# seropositivity
Overall KSHV# positive€ Positive to Lytic K8.1 only¥ Positive to Latent Orf 73 onlyb
Total Positive
(n, %)






Female 127 (66%) 1 104 (66%) 1 73 (62%) 1
Male 66 (34%) 0.96 (0.77-1.19) 54 (34%) 0.98 (0.75-1.26) 44 (38%) 1.16 (0.84-1.60)
Age category
< 40 yrs. 118 (61%) 1 94 (59%) 1 69 (60%) 1
≥ 40 yrs. 75 (39%) 1.06 (0.86-1.31) 64 (41%) 1.00 (0.78-1.29) 48 (41%) 0.99 (0.73-1.35)
Language
Zulu 43 (32%) 1 35 (33%) 1 29 (35%) 1
Other 90 (68%) 1.21 (0.93-1.58) 71 (67%) 1.17 (0.84-1.62) 54 (65%) 1.09 (0.75-1.59)
Has tuberculosis
No 160 (86%) 1 131 (87%) 1 97 (87%) 1
Yes 25 (14%) 1.06 (0.78-1.42) 20 (13%) 1.08 (0.74-1.57) 15 (13%) 1.06 (0.67-1.67)
BMI category
< 18.5 36 (21%) 1 28 (20%) 1 20 (19%) 1
≥ 18.5 137 79%) 1.28 (0.97-1.70) 114 (80%) 1.33 (0.94-1.90) 85 (81%) 1.46 (0.94-2.26)
Hemoglobin
≥ 8.5 g/dL 166 (89%) 1 136 (89%) 1 96 (85%) 1
< 8.5 g/dL 21 (11%) 1.15 (0.84-1.56) 17 (11%) 1.17 (0.80-1.72) 17 (15%) 1.64 (1.11-2.43)
CD4 count
0-50 cells 47 (28%) 1 39 (28%) 1 24 (23%) 1
51-100 cells 39 (23%) 1.18 (0.87-1.62) 29 (21%) 1.03 (0.68-1.55) 28 (27%) 1.61 (0.97-2.66)
101-200 cells 65 (38%) 1.28 (0.97-1.68) 53 (38%) 1.16 (0.75-1.81) 37 (36%) 1.29 (0.72-2.30)
201-350 cells 19 (11%) 0.98 (0.65-1.47) 17 (12%) 0.96 (0.52-1.76) 15 (14%) 1.27 (0.59-2.90)
CD3 count
< 500 cells 41 (21%) 1 34 (22%) 1 22 (19%) 1
≥ 500 cells 152 (79%) 1.35 (1.04-1.76) 124 (78%) 1.31 (0.93-1.84) 95 (81%) 1.62 (1.04-2.54)
CD8 count
< 500 cells 64 (33%) 1 54 (34%) 1 35 (30%) 1
≥ 500 cells 129 (67%) 1.20 (0.96-1.50) 104 (66%) 1.09 (0.81-1.47) 82 (70%) 1.41 (0.96-2.09)
# KSHV = Kaposi sarcoma herpes virus, PR = prevalence ratio estimated from log-binomial regression model. All models adjusted for sex, age and baseline CD4
count
€ KSHV negative individuals used as the comparison group
¥ Those who did not react to lytic K8.1 including the KSHV negative individuals used as the comparison group
b Those who did not react to latent Orf73 including the KSHV negative individuals used as the comparison group
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associated with better markers of immunity in terms of
higher CD3, CD4 and CD8 cell counts.
The high prevalence of KSHV (48%) demonstrated in
this setting is comparable with findings from similar set-
tings among HIV-infected populations [34,35]. In contrast,
KSHV prevalence appears to be much lower in the devel-
oped world among the HIV uninfected but higher among
pregnant women [34] and men who have sex with men
[36]. These findings have fuelled theories of a sexual route
of transmission for KSHV [37]. Such conflicting results are
probably the result of varying routes of transmission of
this virus and much geographic variability in prevalence
rates [38]. A South African study showed rates of KSHV
infection to vary from 35% to 49% across different munici-
palities within one province [34]. Among populations with
a high prevalence of KSHV seropositivity, the route of
infection is likely to be saliva and is acquired during child-
hood and early adult life [39,40]. Sexual and non-sexual
transmission seems to occur in KSHV naïve adult popula-
tions such as men who have sex with men and sex-work-
ers [36,37,41,42].
Advanced age, male gender, nutrition, anemia, concur-
rent tuberculosis and other opportunistic infections have
been demonstrated to be associated with an advanced
stage of HIV disease and mortality among untreated indi-
viduals [13,14,16,17,19-22,37]. Our finding of a positive
association between anemia and KSHV seropositivity
among the group reactive to latent Orf73 is in keeping
with this. However, we found no evidence of an associa-
tion with other poor prognostic features; in fact the KSHV
positive group had higher BMI and CD3, 4 and 8 cell
counts than their KSHV negative counterparts. Among
the KSHV infected individuals, however, those with a
detectable KSHV viral load presented with signs of more
advanced HIV disease including anemia and WHO stage 3
or 4 defining conditions compared to those in whom the
virus was undetectable. KSHV viremia has previously been
associated with the likelihood of development of clinical
Kaposi sarcoma and other signs of advanced HIV disease
including thrombocytopenia and higher HIV viral loads
[43]. KSHV DNA in plasma has also been shown to pre-
dict death among those with clinical Kaposi sarcoma [44].
Detectable KSHV viremia may indicate poor immune con-
trol of KSHV infection [43-45] which in turn may indicate
more advanced HIV disease. Furthermore, KSHV viremia
has been associated with increased risk of clinical Kaposi
sarcoma among HIV infected subjects [45] and, therefore,
HIV/KSHV co-infected subjects with detectable KSHV
viral load may benefit from specific prophylactic strategies
and increased monitoring for KSHV related diseases.
The optical density for lytic and latent KSHV was com-
parable to other work in similar settings with high HIV
prevalence [34]. The optical density for lytic K8.1 KSHV
antigen was higher than that for latent Orf73 and more
individuals were reactive to the lytic antigen. This is in
keeping with the theories that lytic antigen represents
actively replicating virus, as would be seen in the case of
advanced HIV disease, and poor control of the immune
system in the untreated individual [28]. In addition to this,
in our data, those positive to latent Orf73 antigen pre-
sented with markers of less immune suppression and less
advanced disease. Those with higher BMI, higher CD3, 8
and 4 cell counts were more likely to be reactive to latent
Orf73 than those who did not react to latent Orf73
(including the overall KSHV negative group). CD4 and 8
cells play important roles in cell-mediated immunity and
control of viremia in the HIV-infected individual [46,47]
and low absolute numbers of CD4 and 8 cells have been
associated with an increased risk of disease progression
and mortality among HIV-infected persons [18,22-25].
Co-infection with other viruses such as hepatitis,
Epstein-Barr and human papilloma has been shown to
increase the risk of HIV disease progression and mortal-
ity in immune suppressed HIV infected individuals
[48-51]. There is plausible biological evidence that sug-
gests KSHV could impact on disease progression
through stimulation of HIV tat proteins and activation
of HIV replication [52]. Despite this, the KSHV seropo-
sitive group in this study was associated with less
immune suppression and better BMI, particularly
among those seropositive to latent Orf73, an antigen
expressed less often during active replication of the
KSHV virus. One study among a cohort of long term
non-progressors also found no effect of KSHV infection
on persistence of long term non-progressor status [53].
Our findings must be considered in light of possible lim-
itations of the study. Firstly, due to the cross sectional nat-
ure of the analysis, we cannot make inferences about causal
relationships between KSHV and the factors under investi-
gation. As KSHV transmission has been shown to occur
even early in life [39,40], presumably by saliva, temporal
relationships between KSHV infection and the factors con-
sidered are difficult to establish. However, information
about possible associations between KSHV seropositivity
and other known risk factors for HIV disease progression
are useful in generating hypotheses about possible interac-
tions between these viruses. Secondly, it is possible that the
association we demonstrate between less suppression of
the immune system and KSHV seropositivity is due, at
least in part, to survival bias. If KSHV infection is, in fact,
associated with more advanced immune suppression and
subsequent faster HIV disease progression, one could
expect those with KSHV to be at greater risk of mortality
before being able to access HIV treatment and care. Thus,
the KSHV population presenting for treatment may repre-
sent a particularly healthy group of KSHV-infected indivi-
duals who have survived to that point as suggested by
higher BMI and T-lymphocyte subpopulations noted.
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Additionally, despite this high prevalence of KSHV in an
immunologically suppressed population, only one indivi-
dual presented with clinical Kaposi sarcoma. As national
guidelines change and ART is initiated at higher CD4
counts, we may see changes in prevalence and presenting
features of those co-infected with KSHV. Studies focused
on HIV-infected individuals who are not yet eligible for
ART and ideally among a population who have recently
HIV seroconverted may shed light on this point. Thirdly,
in light of the geographic and population differences in
prevalence and routes of transmission of KSHV, it may not
be possible to generalize these results to other populations,
such as those in the developed world.
Conclusions
Despite these limitations, this study offers some insight
into, as yet, unanswered questions around the clinical
effect of KSHV co-infection. We demonstrate a high pre-
valence of co-infection with KSHV among a group of
treatment naïve, HIV-infected adults initiating ART at a
large urban clinic in Johannesburg, South Africa. The
study population was similar to the general population
accessing care at Themba Lethu Clinic with respect to
presenting features. The results may, therefore, be reason-
ably extrapolated to HIV positive individuals accessing
care at urban public sector clinics in South Africa.
Although there appeared to be some immunological dif-
ferences in terms of CD3, CD4 and CD8 cell counts
between the KSHV positive and negative groups, KSHV
seropositivity was not associated with other known risk
factors for disease progression such as age, gender and
concurrent tuberculosis infection among the HIV-infected
untreated population. If we assume that KSHV co-infec-
tion has little or no impact among the untreated popula-
tion, it may follow that KSHV co-infection would have
little effect on outcomes among treated individuals, unless
KSHV has a large direct impact on the effectiveness of
antiretrovirals. Future research efforts in this field should
be focused on longitudinal studies to determine if KSHV
seropositivity, particularly viremia, poses a risk for HIV
treatment outcomes, development of KS immune reconsti-
tution inflammatory syndrome and mortality in the pre-
sence of antiretroviral therapy.
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